Advancells, the stem cell regeneration giant is now all set to explore the B2B segment with an aim to become the global leader in providing a viable option for pharma companies to test their product at an initial stage before going into human trials.

One of the pioneers in stem cell research in India, Advancells has passionately opened new avenues for therapeutic applications of regenerative medicine that is used in adult stem cells. A 10-crore business, claiming to cure a variety of diseases including neurological conditions, orthopaedic issues, kidney, liver and lung diseases, cardiology and cosmetic procedures with a team of professionals spread across Noida, Australia and Bangladesh, Advancells might just be one of the biggest facilitator of regenerative medicine .

The company's biggest strength is manufacturing stem cells, which are used by the startup's partner hospitals and doctors to treat patients. This sector is one of the latest ventures of 41-year-old serial entrepreneur, Vipul Jain, alongside his other businesses. Even though Advancells has plans to provide each patient a complete solution with a 360-degree management of their disease, it is keen to sell the varied cell lines to pharma companies, research institutes, and global research organizations. In pursuit of this,Advancells has already developed more than 10 different cell lines which can be sold to these organizations, including organ specific cell lines and general human stem cell lines.

One of the major concerns for which the company has chosen to offer the regenerative medicine to pharma companies and research institutes is to replace animal testing in drug development with human cell lines. Advancells has already started supplying cell lines to hospitals and doctors.

Vipul Jain, CEO, Advancells, who firmly believes in statistics, says, "Stem cells have turned out to be a better approach to perform testing, especially given that they can assist us with using less animals in the testing procedure. Even better, they could be much more financially savvy than utilizing animal models of experimentation. By choosing stem cells for surveying drug toxicology, biotechnology and pharmaceutical organizations can quickly test new chemicals and mixes and all the more promptly induce the outcomes to people. This sort of testing would happen very soon in the development protocol."

Vipul Jain, an MBA from Rochester Institute of Technology, New York, and founder of Advancells, describes his vision as "to turn Advancells into the most sought after name in regenerative medicine - not just in India, but across the globe." "The highlight of this campaign is that it's the newest chapter focused on broadening how people know Advancells by highlighting all the different ways it can reach out to the masses," says Vipul Jain, Founder,Advancells.